Palisade Bio(PALI.US) Officer Buys US$4,810 in Common Stock
$Palisade Bio(PALI.US)$ Officer Finley John David purchased 1,000 shares of common stock on May 24, 2024 at an average price of $4.81 for a total value of $4,810.Source: Announcement What is statement
Express News | Palisade Bio Inc - Company on Track to Commence Phase 1 Human Clinical Study of Lead Product Candidate, Pali-2108, for Treatment of Uc Before Year End
Express News | Palisade Bio Inc - Preclinical Data Demonstrate Pali-2108 to Be Safe, Effective, and Well Tolerated
Express News | Palisade Bio’s Lead Product Candidate, Pali-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
Data presented at Digestive Disease Week (DDW) 2024Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local
Buy Rating Affirmed for Palisade Bio's PALI-2108 Amid Strong Financials and Promising Partnership
Express News | Palisade Bio Q1 EPS $(4.59) Misses $(4.28) Estimate
Express News | Palisade Bio Inc- Qtrly Shr Loss $ 4.59
Express News | Palisade Bio Inc - Sufficient Cash on Hand to Execute on Business Plan and Reach Clinical and Regulatory Milestones Into 2025
Palisade Bio 1Q Research and Development Expenses $2.2M >PALI
Palisade Bio 1Q Research and Development Expenses $2.2M >PALI
Palisade Bio 1Q Loss/Shr $4.59 >PALI
Palisade Bio 1Q Loss/Shr $4.59 >PALI
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end– Sufficient cash on hand to execute on bu
Palisade Bio | 10-Q: Quarterly report
Palisade Bio Welcomes New Board Member, Eyes Strategic Growth
Express News | Palisade Bio Inc Files for Resale of up to 1.6 Mln Shares by the Selling Stockholders - SEC Filing
Express News | Palisade Bio Announces Closing of $4 Million Private Placement Priced at-the- Market Under Nasdaq Rules
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 07, 2024 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory,
Palisade Bio Appoints Margery Fischbein to Its Board of Directors
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globallyCarlsbad, CA, May 07, 2024 — Pal
12 Health Care Stocks Moving In Friday's After-Market Session
GainersNeuBase Therapeutics (NASDAQ:NBSE) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. Aptevo Therapeutics (
Express News | Palisade Bio Announces $4 Million Private Placement Priced at-the- Market Under Nasdaq Rules
No Data